Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low - Should You Sell?

Key Points

• Structure Therapeutics shares fell to a new 52-week low of $22.10, well below its 50-day and 200-day moving averages of $41.47 and $44.50, respectively.
• Analyst sentiment remains broadly positive despite the decline: MarketBeat reports a “Moderate Buy” consensus and an average price target of $110.91, although some firms have issued sell or strong-sell ratings.
• The clinical-stage biotech is developing GSBR-1290, an oral GLP-1 drug candidate for obesity and type 2 diabetes, but recently missed quarterly EPS estimates and is expected to report a full-year loss.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s share price hit a new 52-week low during trading on Wednesday. The stock traded as low as $22.10 and last traded at $22.31, with a volume of 1,434,790 shares traded. The stock had previously closed at $23.91.

Wall Street Analyst Weigh In

GPCR has been the topic of a number of research analyst reports. Weiss Ratings upgraded Structure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, October 6th. HC Wainwright reissued a "buy" rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Citigroup reissued a "market outperform" rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Citizens Jmp restated a "market outperform" rating and set a $110.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Finally, Wall Street Zen cut Structure Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Structure Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $110.91.

Structure Therapeutics Price Performance

The business has a 50-day simple moving average of $41.47 and a two-hundred day simple moving average of $44.50.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. Sterling Capital Management LLC bought a new stake in Structure Therapeutics during the first quarter valued at about $28,000. IFP Advisors Inc acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $46,000. Assetmark Inc. increased its stake in shares of Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company's stock worth $123,000 after purchasing an additional 449 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of Structure Therapeutics in the first quarter worth about $329,000. Finally, Cetera Investment Advisers increased its stake in shares of Structure Therapeutics by 17.0% in the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company's stock worth $372,000 after purchasing an additional 1,124 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.